

(For the use only of a registered Medical Practitioner or a Hospital or a Laboratory)
Molnupiravir Capsules 400 mg (Areapiravir 400)

COMPOSITION:

Each hard gelatin capsule Contains:

Molnupiravir -----400 mg


Excipients -----q.s

DESCRIPTION:

Molnupiravir is an antiviral drug which is orally active and is developed for the treatment of influenza.

Molecular weight = 329.31

Chemical Formula is C₁₃H₁₉N₃O₇, the structural formula for molnupiravir is:



PHARMACOLOGICAL PROPERTIES

Pharmacodynamic properties

Molnupiravir drug is an orally effective prodrug of the manufactured nucleoside evolved N4-hydroxycytidine. It prompts errors in the viral RNA grouping, stopping the viral replication, lessening the contamination, and restricting infection transmission during the viral RNA replication.

Initially, this Capsule was developed for the treatment of influenza, clinical data suggests that Molnupiravir drug has broad anti-influenza activity, which includes highly potent inhibition of SARS-CoV-2 replication. The two active compounds of this drug are EIDD-2801 and EIDD-1931.

When this drug is administered through the mouth, it absorbs and then converts to its active form, thus making the Molnupiravir treatment initiated as early as possible to restrain the patient's progress into further developing to severe disease and also significantly reduces the infectious phase which the patient may be undergoing.

Pharmacokinetic properties

Molnupiravir is orally bioavailable in non-human primates.

Molnupiravir is hydrolyzed to N4-hydroxycytidine, which distributes into tissues. Once inside cells, N4-hydroxycytidine is phosphorylated to the 5'-triphosphate form.

CLINICAL PARTICULARS

Therapeutic indications

1. Covid-19 infection
2. Seasonal and pandemic flu viruses
3. RNA viruses including the Hepatitis C

Posology and method of administration

The drug was deemed to be safe and was well tolerated up to 800 mg twice a day for five days in healthy trial subjects during phase-1 clinical trials attended in the United Kingdom. In the phase-2 clinical trials, all the patients who took Molnupiravir Capsule were found to have a negative SARS-CoV-2 culture after the five-day treatment duration. Following the nod from the Drugs Controller General of India (DCGI), Phase-III clinical trials have been started to experience the effectiveness of this drug with patients suffering from mild to moderate COVID-19 symptoms.

Contraindications

Patients with known hypersensitivity to molnupiravir or any of the other components of the product.

Undesirable effects

Like all medicines, Molnupiravir can cause side effects, although not everybody gets them. Tell your doctor if any of the side effects gets serious or lasts longer than a few days.

Overdose

Gastric lavage may be indicated; otherwise, no specific antidote exists.

SHELF – LIFE: Refer to carton.

PRESENTATION: Pack of 40 Capsules.

SPECIAL PRECAUTIONS FOR STORAGE: Store below 25°C. Protect from light.